Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Cedars-Sinai Medical Center
Beth Israel Deaconess Medical Center
Queen Mary University of London
University of Arizona
University of Oklahoma
H. Lee Moffitt Cancer Center and Research Institute
Dana-Farber Cancer Institute
NYU Langone Health
University Medical Centre Ljubljana
Washington University School of Medicine
City of Hope Medical Center
CHU de Quebec-Universite Laval
Washington University School of Medicine
H. Lee Moffitt Cancer Center and Research Institute
Tomsk National Research Medical Center of the Russian Academy of Sciences
Institute of Cancer Research, United Kingdom
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University Hospital, Antwerp
University of California, Davis
Memorial Sloan Kettering Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Duke University
University Health Network, Toronto
Larissa University Hospital
Alliance for Clinical Trials in Oncology
Tianjin Medical University Cancer Institute and Hospital
H. Lee Moffitt Cancer Center and Research Institute
Dana-Farber Cancer Institute
AdventHealth
City of Hope Medical Center
Mayo Clinic
National Health Research Institutes, Taiwan
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Massachusetts General Hospital
University of Washington
Zhejiang Cancer Hospital
Memorial Sloan Kettering Cancer Center
Queen Mary University of London
Alliance for Clinical Trials in Oncology
OHSU Knight Cancer Institute
Cedars-Sinai Medical Center
Yale University
Weill Medical College of Cornell University
University of Nebraska